Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits

Epidemiological studies showed that hypercholesterolemia is associated with higher left ventricular mass. Endothelin signaling is activated in hyperlipidemic animals and may contribute to progressive ventricular hypertrophy. Simvastatin has been shown to inhibit endothelin-1. However, the behavior of simvastatin on ventricular hypertrophy in hyperlipidemic animals is not well understood. In this study, we evaluated the hemodynamic, biochemical, and morphological responses to simvastatin in cholesterol-fed (1%) rabbits. The left ventricular weight increased 8 wk after cholesterol feeding compared with that in normocholesterolemic rabbits. Simvastatin at a clinical therapeutic dose (1.2 mg·kg−1·day−1) significantly decreased left ventricular weight by 14% and left ventricular myocyte sizes by 14% as isolated by enzymatic dissociation. Hypercholesterolemia upregulated ventricular preproendothelin-1 mRNA as assessed by real-time quantitative RT-PCR and elevated production of cardiac endothelin-1 concentration. The increased endothelin-1 responses can be inhibited after simvastatin administration. Left ventricular mass indexed by body weight positively correlated with tissue endothelin-1 levels ( P = 0.0003). In Langendorff-perfused rabbit hearts, hyperlipidemia led to significant QT prolongation compared with normocholesterolemia, which can be reversed by administering simvastatin. In contrast, simvastatin-induced beneficial effects were reversed by the addition of mevalonate. The addition of bosentan, a nonspecific endothelin receptor blocker, improved the response in hypercholesterolemic rabbits and did not have additional beneficial effects in simvastatin-treated rabbits. The results of the present study suggest that the antihypertropic and electrocardiographic effects of simvastatin at a clinical therapeutic dose are mediated through inhibition of tissue endothelin-1 expression, which is linked to mevalonate metabolism, and result in an amelioration of cardiomyocyte hypertrophy development by an atherogenic diet.

Download Full-text

INDICATORS OF LEFT VENTRICLE HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH OBESITY AND THEIR INTERCONNECTION WITH POLYMORPHISM OF LYS198ASN GENЕ OF ENDOTHELIN-1

Wiadomości Lekarskie ◽

10.36740/wlek202005125 ◽

2020 ◽

Vol 73 (5) ◽

pp. 972-977

Author(s):

Yuliia O. Smiianova ◽

Liudmyla N. Prystupa ◽

Olha M. Chernatska ◽

Yurii V. Smiianov

Keyword(s):

Arterial Hypertension ◽

Left Ventricular Mass ◽

Body Mass ◽

Ventricular Hypertrophy ◽

Left Ventricular ◽

Endothelin 1 ◽

Ventricular Mass ◽

Left Ventricle Hypertrophy ◽

Polymerase Chain ◽

Ventricle Hypertrophy

The aim of the study was to find dependence of left ventricular hypertrophy indexes to polymorphism of Les198Asn gene endothelin-1 and BMI. Materials and methods: We took research in 160 patients with arterial hypertension, using ECG and polymerase chain reaction (PCR). Groups were divided additionally according to BMI (body mass index). Results: It was found, that patients with obesity had their Left ventricular mass and hypertrophy left ventricular indexes higher, than in patients with normal and increased body weight. Carriers of Asn198Asn and Lys198Asn genotypes Left ventricular mass and hypertrophy left ventricular indexes are higher than in carriers of Lys198Lys genotype. Conclusions: It was determined that in patients-carriers of Asn198Asn genotype, Left ventricular mass (LVMI) and hypertrophy left ventricular indexes (LVMMI) were higher compared to patients-carriers of Lys198Lys and Lys198Asn type, both in men and women. The dependence of LVMI and LVMMI are shown to be higher in patients with obesity than in people with normal and increased body mass.

Download Full-text

The association of ankle brachial index with left ventricular hypertrophy and left ventricular mass index: the Dong-gu study

VASA ◽

10.1024/0301-1526/a000289 ◽

2013 ◽

Vol 42 (4) ◽

pp. 284-291 ◽

Cited By ~ 1

Author(s):

Seong-Woo Choi ◽

Hye-Yeon Kim ◽

Hye-Ran Ahn ◽

Young-Hoon Lee ◽

Sun-Seog Kweon ◽

...

Keyword(s):

Left Ventricular Hypertrophy ◽

Left Ventricular Mass ◽

Ventricular Hypertrophy ◽

Left Ventricular Mass Index ◽

Ankle Brachial Index ◽

Intima Media Thickness ◽

Left Ventricular ◽

Baseline Survey ◽

Ventricular Mass Index ◽

Ventricular Mass

Background: To investigate the association between ankle-brachial index (ABI), left ventricular hypertrophy (LVH) and left ventricular mass index (LVMI) in a general population. Patients and methods: The study population consisted of 8,246 people aged 50 years and older who participated in the baseline survey of the Dong-gu Study conducted in Korea between 2007 and 2010. Trained research technicians measured LV mass using mode M ultrasound echocardiography and ABI using an oscillometric method. Results: After adjustment for risk factors and common carotid artery intima-media thickness (CCA-IMT) and the number of plaques, higher ABIs (1.10 1.19, 1.20 - 1.29, and ≥ 1.30) were significantly and linearly associated with high LVMI (1.10 - 1.19 ABI: β, 3.33; 95 % CI, 1.72 - 4.93; 1.20 - 1.29 ABI: β, 6.51; 95 % CI, 4.02 - 9.00; ≥ 1.30 ABI: β, 14.83; 95 % CI, 6.18 - 23.48). An ABI of 1.10 - 1.19 and 1.20 - 1.29 ABI was significantly associated with LVH (1.10 - 1.19 ABI: OR, 1.35; 95 % CI, 1.19 - 1.53; 1.20 - 1.29 ABI: OR, 1.59; 95 % CI, 1.31 - 1.92) and ABI ≥ 1.30 was marginally associated with LVH (OR, 1.73; 95 % CI, 0.93 - 3.22, p = 0.078). Conclusions: After adjustment for other cardiovascular variables and CCA-IMT and the number of plaques, higher ABIs are associated with LVH and LVMI in Koreans aged 50 years and older.

Download Full-text

Beneficial effects of Sodium glucose co‐transporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus

Journal of Diabetes ◽

10.1111/1753-0407.13209 ◽

2021 ◽

Author(s):

Daisuke Kosugi ◽

Hidefumi Inaba ◽

Yosuke Kaido ◽

Saya Ito ◽

Tomonao Hirohata ◽

...

Keyword(s):

Diabetes Mellitus ◽

Left Ventricular Mass ◽

Left Ventricular ◽

Beneficial Effects ◽

Ventricular Mass ◽

Patients With Diabetes

Download Full-text

ARTERIAL HYPERTENSION ASSOCIATED WITH HYPERURICEMIA: FEATURES OF HEART DAMAGE

Wiadomości Lekarskie ◽

10.36740/wlek202005119 ◽

2020 ◽

Vol 73 (5) ◽

pp. 943-946

Author(s):

Olha M. Chernatska ◽

Liudmyla N. Prystupa ◽

Hanna A. Fadieieva ◽

Alina V. Liashenko ◽

Yuliia O. Smiianova

Keyword(s):

Uric Acid ◽

Left Ventricular Hypertrophy ◽

Arterial Hypertension ◽

Left Ventricular Mass ◽

Ventricular Hypertrophy ◽

Left Ventricular Mass Index ◽

Serum Uric Acid Level ◽

Left Ventricular ◽

Ventricular Mass Index ◽

Ventricular Mass

The aim is the analysis of hyperuricemia influence on the heart features in patients with arterial hypertension. Materials and methods: We include 75 patients with arterial hypertension which were divided in two groups according to the level of uric acid in the blood, 30 practically healthy people. Patients from the I group (n = 40) had arterial hypertension and coexistent hyperuricemia; ІІ (n = 35) – arterial hypertension. Left ventricular mass index was determined for left ventricular hypertrophy confirmation. We used clinical, anthropometric, biochemical, instrumental, statistical method. Serum uric acid level was observed by the reaction with uricase. Left ventricular mass index was calculated as left ventricular mass to body surface area ratio. The results were analyzed statistically by SPSS 21 and Graphpad. Results: Left ventricular mass index was significantly higher (р = 0,0498) in patients from the І group (109,7 ± 3,21) g/m2 comparable with the ІІ (97,6 ± 5,35) g/m2 and increased in proportion to the biggest level of uric acid (r = 0,31; p = 0,04) in patients with arterial hypertension and hyperuricemia. Conclusions: Concentric and excentric left ventricular hypertrophy, increased left ventricular mass index proportionally to uric acid levels (r = 0,31; p = 0,04) is the confirmation of important role of hyperuricemia in the left ventricular hypertrophy development in patients with arterial hypertension.

Download Full-text